Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO ’17 Meeting – TheStreet.com
|
Bluebird, Kite and Juno Delivering CAR–T Cancer Study Updates to ASCO '17 Meeting
TheStreet.com The drug companies engineering T–cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T–cells, or CAR-Ts, will be busy at the American Society of Clinical Oncology (ASCO) annual meeting in June. Investors, however, won't … Broad Range of Clinical Data Evaluating Celgene Therapies to Be Presented at American Society of Clinical Oncology … |
